Gene regulatory potential of nonsteroidal vitamin D receptor ligands.

@article{Perkyl2005GeneRP,
  title={Gene regulatory potential of nonsteroidal vitamin D receptor ligands.},
  author={Mikael Per{\"a}kyl{\"a} and Marjo Malinen and Karl‐Heinz Herzig and Carsten Carlberg},
  journal={Molecular endocrinology},
  year={2005},
  volume={19 8},
  pages={
          2060-73
        }
}
The seco-steroid 1alpha,25-dihydroxyvitamin D3 [1alpha,25(OH)2D3] is a promising drug candidate due to its pleiotropic function including the regulation of calcium homeostasis, bone mineralization and cellular proliferation, differentiation, and apoptosis. We report here a novel class of nonsteroidal compounds, represented by the bis-aromatic molecules CD4409, CD4420, and CD4528, as ligands of the 1alpha,25(OH)2D3 receptor (VDR). Taking the known diphenylmethane derivative LG190178 as a… 

Figures and Tables from this paper

Quantification of the vitamin D receptor-coregulator interaction.

The VDR binding patterns identified in this study may be used to predict functional differences among different tissues expressing different sets of coregulators, thus facilitating the goal of developing tissue- and gene-specific vitamin D response modulators.

Detailed molecular understanding of agonistic and antagonistic vitamin D receptor ligands.

The vitamin D receptor (VDR) is an endocrine member of the nuclear receptor superfamily and binds the biologically most active vitamin D metabolite, 1alpha,25-dihydroxyvitamin D3 (1alpha,25(OH)2D3).

Therapeutic applications for novel non-hypercalcemic vitamin D receptor ligands

The in vitro and in vivo pharmacological actions, including VDR interaction, regulation of cofactor recruitment, pharmacokinetics and cell type or tissue-selective action of VDR ligands with less-calcemic activity are discussed.

Vitamin D receptor ligands: the impact of crystal structures

This review will present and discuss new synthetic agonistic and antagonistic 1α,25(OH)2D3 analogs in the context of the recent insights provided by VDR crystal structures.

Effects of fluorines on nonsecosteroidal vitamin D receptor agonists.

Dynamic and Ligand-Selective Interactions of Vitamin D Receptor with Retinoid X Receptor and Cofactors in Living Cells

Results indicate that ligand-selective conformation may lead to unique cofactor complex formation in a cell context-dependent manner and the development of selective VDR modulators.

References

SHOWING 1-10 OF 45 REFERENCES

Structure Activity Relationship of Carboxylic Ester Antagonists of the Vitamin D3 Receptor

Only a very limited number of structural variations of compound 1 are possible to keep its antagonistic profile, but the tools presented here for their in vitro evaluation allow an accurate prediction of the effects and are suited to screening for even more potent 1α,25(OH)2D3 antagonists.

Molecular evaluation of vitamin D3 receptor agonists designed for topical treatment of skin diseases.

It is demonstrated that the sensitivity in activating the vitamin D3 receptor is already optimal for MC903, but the analog may not be ideal in keeping the receptor active and in selectively triggering 1alpha,25-dihydroxyvitamin D3 signaling pathways.

All natural DR3-type vitamin D response elements show a similar functionality in vitro.

Taken together, this study strongly suggests that DR3-type VDREs alone cannot explain the pleiotropic genomic action of 1alpha,25(OH)(2)D(3), and that the affinity for VDR-RXR heterodimers appears to be the major discriminating parameter between naturalDR3- type VDres.

Selective recognition of vitamin D receptor conformations mediates promoter selectivity of vitamin D analogs.

L ligand-dependent gel-shift assays were used for a comparison of the ability of VD and EB1089 to stabilize VDR-RXR heterodimers on these two VDRE types, and indicated that promoter selectivity of VDR ligands is based on their property to selectively increase affinity for VD REs and very sensitively stabilize V DR conformations in V DR-R XR-VDRE complexes.

Structural evaluation of the agonistic action of a vitamin D analog with two side chains binding to the nuclear vitamin D receptor.

Gemini is an important model compound that allows further insight into the molecular actions of the VDR but is, in parallel, also a promising precursor for the design of even more potent 1alpha,25(OH)2D3 analogs.

Conformational change and enhanced stabilization of the vitamin D receptor by the 1,25-dihydroxyvitamin D3 analog KH1060.

It is shown that increased stabilization of the VDR-KH1060 complex could be an explanation for its high potencies and differences in 1,25-(OH)2vitamin D3- and KH1060-induced conformational changes of theVDR could underlie the increased VDR stability.

Antagonistic Action of a 25-Carboxylic Ester Analogue of 1α,25-Dihydroxyvitamin D3 Is Mediated by a Lack of Ligand-induced Vitamin D Receptor Interaction with Coactivators*

Data suggest that the antagonistic action of ZK159222 is due to a lack of ligand-induced interaction of the VDR with coactivators with a parallel ligand sensitivity, which is sufficient for competition with the natural hormone for VDR binding.

Response element and coactivator-mediated conformational change of the vitamin D(3) receptor permits sensitive interaction with agonists.

The induction of response element- and coactivator-modulated VDR conformations appears to be a key step for the gene regulatory function of a VDR agonist.